UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 62

Sortiert nach

518 CX-4945, an inhibitor of protein kinase CK2, disrupts DNA damage repair, potentiates apoptosis and enhances antitumor activity of gemcitabine in a model of ovarian cancer

European journal of cancer supplements, 2010, Vol.8 (7), p.165-166

2010

Volltextzugriff (PDF)

7-(4 H-1,2,4-Triazol-3-yl)benzo[ c][2,6]naphthyridines: A novel class of Pim kinase inhibitors with potent cell antiproliferative activity

Bioorganic & medicinal chemistry letters, 2011-11, Vol.21 (22), p.6687-6692

2011

Volltextzugriff (PDF)

99 Combined inhibition of EGFR and protein kinase CK2 synergistically blocks phosphorylation of ribosomal protein S6, induces apoptosis in cancer cells and displays enhanced antitumor activity in xenograft models

European journal of cancer supplements, 2010, Vol.8 (7), p.39-39

2010

Volltextzugriff (PDF)

Abstract 1106: Alvocidib potentiates the activity of venetoclax in preclinical models of multiple myeloma

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.1106-1106

2017

Volltextzugriff (PDF)

Abstract 235: AXL inhibition leads to a reversal of a mesenchymal phenotype sensitizing cancer cells to targeted agents and immuno-oncology therapies

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.235-235

2016

Volltextzugriff (PDF)

Abstract 2560: The CK2 inhibitor CX-4945 enhances the antitumor activity of EGFR-targeted agents by attenuating signaling in the PI3K/AKT/mTOR pathway

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.2560-2560

2011

Volltextzugriff (PDF)

Abstract 2698: Combination strategies to target super enhancer transcriptional activity by CDK9 and BRD4 inhibition in acute myeloid leukemia

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.2698-2698

2015

Volltextzugriff (PDF)

Abstract 3604: Targeting the PIM kinases in combination with BTK inhibition is synergistic in preclinical models of B-cell malignancies

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3604-3604

2015

Volltextzugriff (PDF)

Abstract 3728: Targeting MCL-1 expression, through the inhibition of CDK9 and super enhancer driven transcription, offers multiple opportunities for rational drug combinations

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.3728-3728

2016

Volltextzugriff (PDF)

Abstract 3765: Discovery and biological characterization of CX-8184, a potent inhibitor of protein kinase CK2

Cancer research (Chicago, Ill.), 2012-04, Vol.72 (8_Supplement), p.3765-3765

2012

Volltextzugriff (PDF)

Abstract 3804: The potent AXL kinase inhibitor, TP-0903, is active in pre-clinical models of EGFR positive non-small cell lung cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.3804-3804

2019

Volltextzugriff (PDF)

Abstract 4823: Alvocidib enhances the efficacy of cytarabine and daunorubicin (7+3) in non-clinical models of acute myeloid leukemia

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.4823-4823

2018

Volltextzugriff (PDF)

Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.5133-5133

2017

Volltextzugriff (PDF)

Abstract 5494: CX-4945, an inhibitor of protein kinase CK2, potentiates the antitumor activity of platinum chemotherapy in models of ovarian cancer by preventing phosphorylation of XRCC1 and MDC1 and disrupting DNA damage repair

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.5494-5494

2011

Volltextzugriff (PDF)

Abstract 5813: Pharmacodynamic biomarker strategies for CDK9 inhibition

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5813-5813

2020

Volltextzugriff (PDF)

Abstract 883: Alvocidib-mediated inhibition of CDK9 upregulates BIM via suppression of miR17-92

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.883-883

2018

Volltextzugriff (PDF)

Abstract A246: Discovery of selective small molecule Pan-Pim kinase inhibitors with potent oral efficacy in murine xenograft models

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.A246-A246

2009

Volltextzugriff (PDF)

Abstract B024: PKM2 activation suppresses cellular ROS scavenging capacity and potentiates doxorubicin antitumor activity

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B024-B024

2018

Volltextzugriff (PDF)

Abstract B178: Targeting Myc in triple-negative breast cancer models through the dual inhibition of PIM kinases and CDK9

Molecular cancer therapeutics, 2018-01, Vol.17 (1_Supplement), p.B178-B178

2018

Volltextzugriff (PDF)

Abstract C081: Targeting CDK9 and MCL1 in castration-sensitive and resistant prostate cancer models

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.C081-C081

2019

Volltextzugriff (PDF)

Abstract C198: CX-4945, a novel small molecule inhibitor of CK2 protein kinase, reduces hyperactivated Akt signaling and synergizes with Akt inhibitors in breast cancer cells

Molecular cancer therapeutics, 2009-12, Vol.8 (12_Supplement), p.C198-C198

2009

Volltextzugriff (PDF)

Abstract C202: CDK9 inhibition synergizes with BRD4 inhibitor-mediated super enhancer transcriptional repression in multiple preclinical tumor models

Molecular cancer therapeutics, 2015-12, Vol.14 (12_Supplement_2), p.C202-C202

2015

Volltextzugriff (PDF)

The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease

Blood, 2016-12, Vol.128 (22), p.263-263

2016

Volltextzugriff (PDF)

ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease

Blood, 2015-12, Vol.126 (23), p.273-273

2015

Volltextzugriff (PDF)

An alvocidib-containing regimen is highly effective in AML patients through a mechanism dependent on MCL1 expression and function

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.7062-7062

2015

Volltextzugriff (PDF)

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(61)
Mit Volltextzugriff
(61)

Publikationsform

Artikel
(62)

Sprache

Englisch
(62)
Japanisch
(13)

Erscheinungsjahr

n.n

Thema

Science & Technology
(24)
Humans
(20)
Life Sciences & Biomedicine
(20)
Cell Line, Tumor
(13)
Animals
(11)
Biological And Medical Sciences
(10)
Casein Kinase Ii - Antagonists & Inhibitors
(10)
Chemistry, Medicinal
(10)
Mice
(10)
Pharmacology & Pharmacy
(10)
Chemistry
(9)
Oncology
(9)
Physical Sciences
(9)
Medical Sciences
(8)
Naphthyridines - Pharmacology
(8)
Antineoplastic Agents - Pharmacology
(7)
Neoplasms - Drug Therapy
(7)
Pharmacology. Drug Treatments
(7)
Structure-Activity Relationship
(7)
Cancer
(6)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

518 CX-4945, an inhibitor of protein kinase CK2, disrupts DNA damage repair, potentiates apoptosis and enhances antitumor activity of gemcitabine in a model of ovarian cancer

7-(4 H-1,2,4-Triazol-3-yl)benzo[ c][2,6]naphthyridines: A novel class of Pim kinase inhibitors with potent cell antiproliferative activity

99 Combined inhibition of EGFR and protein kinase CK2 synergistically blocks phosphorylation of ribosomal protein S6, induces apoptosis in cancer cells and displays enhanced antitumor activity in xenograft models

Abstract 1106: Alvocidib potentiates the activity of venetoclax in preclinical models of multiple myeloma

Abstract 235: AXL inhibition leads to a reversal of a mesenchymal phenotype sensitizing cancer cells to targeted agents and immuno-oncology therapies

Abstract 2560: The CK2 inhibitor CX-4945 enhances the antitumor activity of EGFR-targeted agents by attenuating signaling in the PI3K/AKT/mTOR pathway

Abstract 2698: Combination strategies to target super enhancer transcriptional activity by CDK9 and BRD4 inhibition in acute myeloid leukemia

Abstract 3604: Targeting the PIM kinases in combination with BTK inhibition is synergistic in preclinical models of B-cell malignancies

Abstract 3728: Targeting MCL-1 expression, through the inhibition of CDK9 and super enhancer driven transcription, offers multiple opportunities for rational drug combinations

Abstract 3765: Discovery and biological characterization of CX-8184, a potent inhibitor of protein kinase CK2

Abstract 3804: The potent AXL kinase inhibitor, TP-0903, is active in pre-clinical models of EGFR positive non-small cell lung cancer

Abstract 4823: Alvocidib enhances the efficacy of cytarabine and daunorubicin (7+3) in non-clinical models of acute myeloid leukemia

Abstract 5133: TP-1287, an oral prodrug of the cyclin-dependent kinase-9 inhibitor alvocidib

Abstract 5494: CX-4945, an inhibitor of protein kinase CK2, potentiates the antitumor activity of platinum chemotherapy in models of ovarian cancer by preventing phosphorylation of XRCC1 and MDC1 and disrupting DNA damage repair

Abstract 5813: Pharmacodynamic biomarker strategies for CDK9 inhibition

Abstract 883: Alvocidib-mediated inhibition of CDK9 upregulates BIM via suppression of miR17-92

Abstract A246: Discovery of selective small molecule Pan-Pim kinase inhibitors with potent oral efficacy in murine xenograft models

Abstract B024: PKM2 activation suppresses cellular ROS scavenging capacity and potentiates doxorubicin antitumor activity

Abstract B178: Targeting Myc in triple-negative breast cancer models through the dual inhibition of PIM kinases and CDK9

Abstract C081: Targeting CDK9 and MCL1 in castration-sensitive and resistant prostate cancer models

Abstract C198: CX-4945, a novel small molecule inhibitor of CK2 protein kinase, reduces hyperactivated Akt signaling and synergizes with Akt inhibitors in breast cancer cells

Abstract C202: CDK9 inhibition synergizes with BRD4 inhibitor-mediated super enhancer transcriptional repression in multiple preclinical tumor models

The ALK-2 Inhibitor, TP-0184, Demonstrates High Distribution to the Liver Contributing to Significant Preclinical Efficacy in Mouse Models of Anemia of Chronic Disease

ALK2 Inhibition Via TP-0184 Abrogates Inflammation-Induced Hepcidin Expression and Is a Potential Therapeutic for Anemia of Chronic Disease

An alvocidib-containing regimen is highly effective in AML patients through a mechanism dependent on MCL1 expression and function

Suchergebnisse filtern